Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosi...

Podrobná bibliografie
Hlavní autoři:	McLornan, DP, Godfrey, AL, Green, A, Frewin, R, Arami, S, Brady, J, Butt, NM, Cargo, C, Ewing, J, Francis, S, Garg, M, Harrison, C, Innes, A, Khan, A, Knapper, S, Lambert, J, Mead, A, McGregor, A, Neelakantan, P, Psaila, B, Somervaille, TCP, Woodley, C, Nangalia, J, Cross, NCP, McMullin, MF
Další autoři:	BSH Committee
Médium:	Journal article
Jazyk:	English
Vydáno:	Wiley 2023

Podobné jednotky

A guideline for the diagnosis and management of polycythaemia vera. A British Society for haematology guideline
Autor: McMullin, M, a další
Vydáno: (2018)

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis
Autor: McMullin, M, a další
Vydáno: (2018)

Allogeneic stem cell transplantation for myelofibrosis in 2012.
Autor: McLornan, D, a další
Vydáno: (2012)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
Autor: Reilly, J, a další
Vydáno: (2014)

Guideline for the diagnosis and management of myelofibrosis.
Autor: Reilly, J, a další
Vydáno: (2012)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
Autor: Bassiony S, a další
Vydáno: (2020-09-01)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
Autor: Verstovsek, S, a další
Vydáno: (2021)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
Autor: P. Harrington, a další
Vydáno: (2022-06-01)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
Autor: Mead, AJ, a další
Vydáno: (2022)

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm
Autor: Salisbury, RA, a další
Vydáno: (2021)

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
Autor: Mclornan, D, a další
Vydáno: (2012)

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies
Autor: Mesa, RA, a další
Vydáno: (2023)

Mutational spectrum defines primary and secondary myelofibrosis
Autor: Ken I. Mills, a další
Vydáno: (2014-01-01)

Guideline for the diagnosis and management of myelofibrosis
Autor: Reilly, J, a další
Vydáno: (2012)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
Autor: Reilly, J, a další
Vydáno: (2014)

Low-dose thalidomide in myelofibrosis
Autor: Robert Weinkove, a další
Vydáno: (2008-07-01)

A retrospective real world evidence study to review the current treatment pathways for myelofibrosis from across the United Kingdom (the REALISM UK study)
Autor: Mead, A, a další
Vydáno: (2019)

Guideline for the investigation and management of eosinophilia
Autor: Butt, N, a další
Vydáno: (2017)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
Autor: Donal P. McLornan, a další
Vydáno: (2019-04-01)

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
Autor: Stephen T. Oh, a další
Vydáno: (2024-02-01)

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
Autor: Ruben A. Mesa, a další
Vydáno: (2023-05-01)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
Autor: Ruben A. Mesa, a další
Vydáno: (2023-11-01)

Feasibility of recruitment of patients withMyeloproliferative Neoplasms into the TAPfunded TAMARIN study
Autor: Harrison, C, a další
Vydáno: (2018)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
Autor: McIlroy, G, a další
Vydáno: (2025)

Equivalence of BCSH and WHO diagnostic criteria for ET
Autor: Harrison, C, a další
Vydáno: (2016)

The soldier and the post-conflict state
Autor: McMullin, J, a další
Vydáno: (2006)

The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders
Autor: Cross, NCP, a další
Vydáno: (2021)

Practical management of patients with myelofibrosis receiving ruxolitinib.
Autor: Harrison, C, a další
Vydáno: (2013)

Ruxolitinib induces changes in histone modification status in patients entered into the MAJIC clinical trial
Autor: McPherson, S, a další
Vydáno: (2018)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
Autor: Adam J. Mead, a další
Vydáno: (2022-03-01)

Intravesical recurrence of chromophobe renal cell carcinoma
Autor: Niall P. Kelly, a další
Vydáno: (2023-09-01)

A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis
Autor: Psaila, B, a další
Vydáno: (2017)

In utero origin of myelofibrosis presenting in adult monozygotic twins
Autor: Sousos, N, a další
Vydáno: (2022)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
Autor: Graham McIlroy, a další
Vydáno: (2025-01-01)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
Autor: A. Vannucchi, a další
Vydáno: (2022-06-01)

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
Autor: Chowdhury, O, a další
Vydáno: (2018)

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis
Autor: Sousos, N, a další
Vydáno: (2020)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
Autor: Greenfield, G, a další
Vydáno: (2020)

S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY
Autor: F. Passamonti, a další
Vydáno: (2022-06-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
Autor: Butt, N, a další
Vydáno: (2019)